One dose of SARS-CoV-2 vaccine exponentially increases antibodies in individuals who have recovered from symptomatic COVID-19
One dose of SARS-CoV-2 vaccine exponentially increases antibodies in individuals who have recovered from symptomatic COVID-19
复制标题
DOI：
10.1172/jci149154
复制
发表时间：
2021-06-15
影响因子：
15.9
通讯作者：
Rescigno, Maria
中科院分区：
文献类型：
--
作者：
Levi, Riccardo;Azzolini, Elena;Rescigno, Maria
背景资料。目前正在使用的新冠肺炎疫苗需要2剂才能实现最佳保护。目前，没有迹象表明接触过SARS-CoV-2病毒的人是否应该接种疫苗，或者他们是否应该接种1或2剂疫苗。方法：我们测试了124名卫生保健专业人员在接种辉瑞/生物技术疫苗后产生的抗体反应，其中57人有既往有或没有症状的SARS-CoV-2接触史。结果：与幼稚的受试者相比，接触SARS-CoV-2病毒的个体在第一次接种后5-18天内，疫苗后抗体呈指数级增加(P<；0.0001)。在多元线性回归(LR)模型中，我们发现抗体应答依赖于免疫球蛋白疫苗滴度和暴露于SARS-CoV-2。在有症状的SARS-CoV-2暴露者中，第二针免疫球蛋白在第二针后达到平台期，自愿不接受第二针的人(n=7)保留了他们的抗体反应。胃肠道症状、肌肉疼痛和发热与增强的免疫球蛋白反应显著正相关。相反，所有无症状/缺乏症状和未暴露的个体在第二次接种后都显示出显著的增加。结论：在有症状的SARS-CoV-2暴露者中，一剂疫苗足以达到高滴度的抗体，这表明没有必要第二次接种，特别是在目前疫苗短缺的情况下。
BACKGROUND. The COVID-19 vaccines currently in use require 2 doses to achieve optimal protection. Currently, there is no indication as to whether individuals who have been exposed to SARS-CoV-2 should be vaccinated, or whether they should receive 1 or 2 vaccine doses.METHODS. We tested the antibody response developed after administration of the Pfizer/BioNTech vaccine in 124 health care professionals, of whom 57 had a previous history of SARS-CoV-2 exposure with or without symptoms.RESULTS. Postvaccine antibodies in SARS-CoV-2-exposed individuals increased exponentially within 5 to 18 days after the first dose compared to naive subjects (P < 0.0001). In a multivariate linear regression (LR) model we showed that the antibody response depended on the IgG prevaccine titer and on the exposure to SARS-CoV-2. In symptomatic SARS-CoV-2-exposed individuals, IgG reached a plateau after the second dose, and those who voluntarily refrained from receiving the second dose (n = 7) retained their antibody response. Gastrointestinal symptoms, muscle pain, and fever markedly positively correlated with increased IgG responses. By contrast, all asymptomatic/paucisymptomatic and unexposed individuals showed an important increase after the second dose.CONCLUSION. One vaccine dose is sufficient in symptomatic SARS-CoV-2-exposed subjects to reach a high titer of antibodies, suggesting no need for a second dose, particularly in light of current vaccine shortage.